Welcome to our dedicated page for Black Diamond Therapeutics news (Ticker: BDTX), a resource for investors and traders seeking the latest updates and insights on Black Diamond Therapeutics stock.
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) is a leading precision oncology medicine company headquartered in Cambridge, Massachusetts. Founded in 2014, the company focuses on the discovery and development of small molecule, tumor-agnostic therapies designed to target families of oncogenic mutations across various cancers.
The core of Black Diamond’s innovative approach lies in its proprietary Mutation-Allostery-Pharmacology (MAP) platform. This platform enables the identification and targeting of allosteric mutations in key cancer-related kinases, offering new therapeutic options for patients with limited treatments available.
The company’s lead product candidate, BDTX-189, is a potent inhibitor targeting non-canonical and oncogenic mutations of ERBB kinases, including the epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The development pipeline also includes BDTX-1535, an advanced fourth-generation EGFR inhibitor, and BDTX-4933, targeting KRAS, NRAS, and BRAF mutations in solid tumors.
Recent clinical updates highlight the potential of BDTX-1535 in treating non-small cell lung cancer (NSCLC) and glioblastoma (GBM), demonstrating efficacy against over 50 clinically relevant non-classical EGFR mutations and resistance mutations like C797S. This candidate is currently advancing through Phase 2 trials, with promising results expected in 2024.
Black Diamond Therapeutics has also established significant collaborations and partnerships to bolster its research and development efforts. These collaborations aim to enhance the understanding of mutation landscapes and accelerate the delivery of new therapies to patients.
For more information, visit Black Diamond Therapeutics.
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) has announced that its President and CEO, David M. Epstein, Ph.D., will present an update on the company's progress at the J.P. Morgan 39th Annual Virtual Healthcare Conference. The presentation is scheduled for January 12, 2021, at 7:30 AM ET. A live webcast will be available on the company's investor relations website, with a replay lasting three weeks. Black Diamond focuses on precision oncology, targeting undrugged mutations in genetically defined cancers via its MAP platform.
Black Diamond Therapeutics, a precision oncology medicine company, announced that its CEO, David M. Epstein, will present an update on the company's advancements at the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. The presentation will be available via webcast starting at the conference's beginning and archived for three weeks on the company’s investor relations website. Black Diamond integrates its proprietary Mutation-Allostery-Pharmacology platform to discover small molecule therapies targeting genetically defined cancers.
Black Diamond Therapeutics (Nasdaq: BDTX) has nominated BDTX-1535 as a development candidate for treating glioblastoma multiforme (GBM), initiating IND-enabling studies. Pre-clinical data presented at the 2020 Society for Neuro-Oncology Annual Meeting shows that BDTX-1535 effectively inhibits various oncogenic EGFR mutations linked to GBM and can penetrate the blood-brain barrier. These findings support BDTX-1535's potential to transform GBM treatment, marking a significant step in Black Diamond's commitment to innovative cancer therapies.
Black Diamond Therapeutics (Nasdaq: BDTX) announced that David M. Epstein, Ph.D., President and CEO, will present at the Jefferies 2020 Virtual London Healthcare Conference. The event occurs on November 18, 2020, at 2:40 PM GMT/9:40 AM ET. The presentation will focus on the company's progress in developing precision oncology therapies targeting genetically defined cancers.
A live webcast is accessible via their investor relations page, with a replay available for three weeks post-event.
Black Diamond Therapeutics (Nasdaq: BDTX) reported significant progress in its Phase 1/2 clinical trial of BDTX-189, with the Phase 1 portion expected to complete by mid-2021. Financially, the company holds $333.1 million in cash as of September 30, 2020, sufficient to fund operations into 2023. The company also appointed Robert A. Ingram as Chairman and Rachel Humphrey, M.D., as Chief Medical Officer, enhancing its leadership. R&D expenses have increased to $12.9 million, reflecting growth initiatives.
Black Diamond Therapeutics (Nasdaq: BDTX) reported promising pre-clinical results for its lead candidate, BDTX-189, at the 32nd EORTC-NCI-AACR Virtual Symposium. The data indicate BDTX-189 can inhibit allosteric EGFR and HER2 mutations while sparing wild-type EGFR, potentially reducing toxicity. BDTX-189 showed effective tumor regression in various models, including patient-derived xenografts. The candidate is advancing to Phase 1/2 clinical trials (MasterKey-01) in patients with advanced solid tumors. BDTX-189 has received Fast Track designation from the FDA for specific mutations in solid tumors.
Black Diamond Therapeutics (Nasdaq: BDTX) announced the presentation of pre-clinical data for its lead candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium on Molecular Targets and Cancer Therapeutics on October 25, 2020. BDTX-189 is designed as an irreversible small molecule inhibitor targeting oncogenic mutations in EGFR and HER2. This presentation may offer insights into treating genetically defined cancers, as no FDA-approved therapies currently exist for these specific mutations. The findings could represent a significant advancement in precision oncology.
Black Diamond Therapeutics (Nasdaq: BDTX) has announced the appointment of Robert A. Ingram as Chairman of its Board of Directors, succeeding founding Chairman Brad Bolzon, who will remain on the board. Ingram, a seasoned leader in the pharmaceutical industry with experience at GlaxoWellcome and GlaxoSmithKline, is expected to steer the company towards its goal of advancing precision oncology therapies. Black Diamond possesses a proprietary MAP platform aimed at targeting genetically defined cancers. The company is committed to transforming the oncology landscape through innovative small molecule therapies.
Black Diamond Therapeutics has appointed Robert A. Ingram as Chairman of its Board of Directors, effective immediately. Ingram, a notable figure in the pharmaceutical industry, previously served as CEO and Chairman of GlaxoWellcome and played a key role in forming GlaxoSmithKline. His experience is expected to bolster Black Diamond’s strategy in precision oncology, particularly in developing tumor-agnostic therapies. The company's MAP platform aims to identify and treat genetically defined cancers.
Black Diamond Therapeutics, a precision oncology company, announced that its CEO, David M. Epstein, Ph.D., will present at the Morgan Stanley 18th Annual Global Healthcare Conference on September 15, 2020, at 2:45 PM ET. The presentation aims to update on the company’s progress in developing small molecule, tumor-agnostic therapies for genetically defined cancers. A live webcast will be available on their investor relations website, with a replay accessible for three weeks. Black Diamond employs a proprietary MAP platform to target undrugged mutations in cancer.
FAQ
What is the current stock price of Black Diamond Therapeutics (BDTX)?
What is the market cap of Black Diamond Therapeutics (BDTX)?
What does Black Diamond Therapeutics do?
Where is Black Diamond Therapeutics headquartered?
What is the Mutation-Allostery-Pharmacology (MAP) platform?
What is BDTX-189?
What are the key clinical-stage programs at Black Diamond?
What recent achievements has Black Diamond Therapeutics made?
What are upcoming milestones for Black Diamond Therapeutics?
What collaborations is Black Diamond involved in?
When was Black Diamond Therapeutics founded?
How does BDTX-1535 differ from existing therapies?
